Figure 1.

Clinical response to BCDT treatment in lupus erythematosus patients with severe cutaneous manifestations treated at UCLH. (a) Bars represent the mucocutaneous BILAG score at zero, three and six months after BCDT in 14 SLE patients. Numbers on the x-axis refer to the patients as described in Table 1. BILAG A indicates a severe mucocutaneous involvement, BILAG B moderate, BILAG C mild and BILAG D inactive mucocutaneous disease. (b) BILAG scores of eight SLE patients who relapsed and received a second cycle of BCDT (mucocutaneous score at zero, three and six months after BCDT).